At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Closed 02-02 16:00:00 EST
89.84
+1.39
+1.57%
盘后88.40
-1.44-1.60%
19:57 EST
High92.06Low87.55Vol846.15K
Open87.58D1 Closing88.45Amplitude5.10%
Mkt Cap6.21BTradable Cap4.40BTotal Shares69.14M
T/O76.69MT/O Rate1.73%Tradable Shares49.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Structure Therapeutics emerges as top M&A target for big pharma, Axios says
TIPRANKS  ·  01-30
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It
Benzinga_recent_news  ·  01-23
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It
Structure Therapeutics Inc : JP Morgan Raises Target Price to $105 From $65
THOMSON REUTERS  ·  01-22
Structure Therapeutics Inc : JP Morgan Raises Target Price to $105 From $65
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Goldman Sachs
TIPRANKS  ·  01-20
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Goldman Sachs
24H | Springview Rockets Another 16% After a 674% Rally; GPCR Jumps 6% as It Expects Pills to Capture up to 50% of GLP-1 Obesity Market; Hesai Gains 3%
Tiger Newspress  ·  01-16
24H | Springview Rockets Another 16% After a 674% Rally; GPCR Jumps 6% as It Expects Pills to Capture up to 50% of GLP-1 Obesity Market; Hesai Gains 3%
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Benzinga_recent_news  ·  01-16
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Structure Therapeutics CEO Voices Concerns Over Generic Competition for Weight-Loss Drugs: Challenges Loom Even Before Market Approval
Stock News  ·  01-15
Structure Therapeutics CEO Voices Concerns Over Generic Competition for Weight-Loss Drugs: Challenges Loom Even Before Market Approval
Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030
Reuters  ·  01-15
Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030
Structure Therapeutics CEO Expects Pills to Capture 25% to 50% of Glp-1 Weight-Loss Market by 2030
THOMSON REUTERS  ·  01-15
Structure Therapeutics CEO Expects Pills to Capture 25% to 50% of Glp-1 Weight-Loss Market by 2030
Structure Therapeutics CEO Says Strategic Partner for Commercialization of Its Medicine Needs to Have Strong Relationships With Primary Care Doctors
THOMSON REUTERS  ·  01-15
Structure Therapeutics CEO Says Strategic Partner for Commercialization of Its Medicine Needs to Have Strong Relationships With Primary Care Doctors
What to Watch in the Day Ahead - Wednesday, January 14
Reuters  ·  01-14
What to Watch in the Day Ahead - Wednesday, January 14
Structure Therapeutics rises 14.1%
TIPRANKS  ·  01-14
Structure Therapeutics rises 14.1%
What to Watch in the Day Ahead - Tuesday, January 13
Reuters  ·  01-13
What to Watch in the Day Ahead - Tuesday, January 13
Funding for Risky Biotechs Is Returning -- WSJ
Dow Jones  ·  01-13
Funding for Risky Biotechs Is Returning -- WSJ
Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation
Reuters  ·  01-13
Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation
Septerna to Present GPCR Pipeline Updates at JPM Conference
TIPRANKS  ·  01-12
Septerna to Present GPCR Pipeline Updates at JPM Conference
Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Dow Jones  ·  01-09
Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%
Tiger Newspress  ·  01-07
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%
Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%
Tiger Newspress  ·  01-06
Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%
BRIEF-Structure Therapeutics Inc - Gasherbrum Entered Agreement With Genentech And Roche - SEC Filing
Reuters  ·  01-06
BRIEF-Structure Therapeutics Inc - Gasherbrum Entered Agreement With Genentech And Roche - SEC Filing

Introduction

Company Name.
STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Issue price:
--